RxDoctor Payments Data

David Rivera, MD

Rheumatology · Zephyrhills, FLNPI 1417246356

Payments from drug & device makers

$80,393in general payments, 2019–2025

Across 1,356 payments — averaging $59.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$59K
  • Amgen$5K
  • Novartis$3K
  • Sobi, Inc$2K
  • Johnson & Johnson$2K
  • UCB, Inc.$2K
  • plus $8K from 33 others

What the payments were for

  • Consulting fees$1,8232%
  • Speaking & faculty fees$46,50058%
  • Travel & lodging$4,9606%
  • Food & beverage$26,92333%
  • Education$1870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,393 in reported general payments places this provider in the 75th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$1,490,770
Medicare patients
728
Services billed
94,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab155$1,124,686
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$384,824
RinvoqUpadacitinib52$333,624
Enbrel SureclickEtanercept42$318,410
Cosentyx Sensoready (2 Pens)Secukinumab26$227,652
Gamunex-CImmune Globul G/Gly/Iga Avg 4622$178,031
Orencia ClickjectAbatacept26$160,948
Xeljanz XrTofacitinib Citrate28$159,718
XeljanzTofacitinib Citrate16$107,465
OtezlaApremilast21$99,085
Actemra ActpenTocilizumab29$90,477
KineretAnakinra13$73,818
BenlystaBelimumab14$67,795
Evenity (2 Syringes)Romosozumab-Aqqg16$39,739
OlumiantBaricitinib11$31,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Xeljanz$1,088$492,28930 claims
AbbVieRinvoq$59,112$333,62452 claims
AmgenOtezla, Evenity (2 Syringes), Prolia$5,040$164,98052 claims
GSKBenlysta$599$67,79514 claims
Lilly USA, LLCOlumiant$1,317$31,14711 claims
Scilex Pharmaceuticals Inc.Colchicine$21$86818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →